Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S® coated modified release formulations of mesalamine, such as Asacol®, remain among the most popular choices. We here review the current und...

Full description

Bibliographic Details
Main Authors:	Doherty, Glen A, Peppercorn, Mark A
Format:	Online
Language:	English
Published:	Dove Medical Press 2009
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108647/

id	pubmed-3108647
recordtype	oai_dc
spelling	pubmed-31086472011-06-21 Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease Doherty, Glen A Peppercorn, Mark A Review 5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S® coated modified release formulations of mesalamine, such as Asacol®, remain among the most popular choices. We here review the current understanding of the mechanism of action of 5-ASA in inflammatory bowel disease. We evaluate evidence supporting the efficacy and safety of modified release mesalamine for both induction and remission maintenance in UC, including a review of the data from the recent ASCEND studies. We also examine the controversial issue of the role of mesalamine in treatment of Crohn’s disease (CD) and highlight data supporting its use following surgically induced remission of CD. Evidence supporting the use of mesalamine as prophylaxis for colorectal cancer and dysplasia will be considered. Finally, recent developments in our understanding of how to use modified release mesalamine in a safe and cost-effective manner are evaluated, including discussion of the importance of studying patient non-adherence as a key component of future studies in this area. Dove Medical Press 2009-12-08 /pmc/articles/PMC3108647/ /pubmed/21694838 Text en © 2009 Doherty and Peppercorn, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Doherty, Glen A Peppercorn, Mark A
spellingShingle	Doherty, Glen A Peppercorn, Mark A Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
author_facet	Doherty, Glen A Peppercorn, Mark A
author_sort	Doherty, Glen A
title	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
title_short	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
title_full	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
title_fullStr	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
title_full_unstemmed	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
title_sort	update on the role of modified release mesalamine in the management of ulcerative colitis and crohn’s disease
description	5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S® coated modified release formulations of mesalamine, such as Asacol®, remain among the most popular choices. We here review the current understanding of the mechanism of action of 5-ASA in inflammatory bowel disease. We evaluate evidence supporting the efficacy and safety of modified release mesalamine for both induction and remission maintenance in UC, including a review of the data from the recent ASCEND studies. We also examine the controversial issue of the role of mesalamine in treatment of Crohn’s disease (CD) and highlight data supporting its use following surgically induced remission of CD. Evidence supporting the use of mesalamine as prophylaxis for colorectal cancer and dysplasia will be considered. Finally, recent developments in our understanding of how to use modified release mesalamine in a safe and cost-effective manner are evaluated, including discussion of the importance of studying patient non-adherence as a key component of future studies in this area.
publisher	Dove Medical Press
publishDate	2009
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108647/
_version_	1611457688094375936

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

Similar Items